Anti-Human CD47 Reference Antibody (Letaplimab, RUO)
- Catalog number: BS10716
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Description: Letaplimab (BS10716) is a research-grade recombinant antibody targeting CD47. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG4-Kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 3.5mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: LeukocytesurfaceantigenCD47,CD47,AntigenicsurfacedeterminantproteinOA3,IAP,Integrin-associatedprotein,ProteinMER6,MER6
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CD47,IBI-188,CAS:2283356-07-8
Background: Leukocyte surface antigen CD47 (MER6) is a ~35 kDa protein. Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. Involved in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Plays a role in modulating pulmonary endothelin EDN1 signaling. Modulates nitrous oxide (NO) signaling, in response to THBS1, hence playing a role as a pressor agent, supporting blood pressure. CD47 is the therapeutic target of magrolimab (clinical).
References:
1. Latour, S. et al. (2001) Journal of immunology (Baltimore, Md. : 1950) 167, 2547-54. PMID: 11509594
2. Piccio, L. et al. (2005) Blood 105, 2421-7. PMID: 15383453
3. Isenberg, JS. et al. (2009) The Journal of biological chemistry 284, 1116-25. PMID: 19004835
4. Lindberg, FP. et al. (1993) The Journal of cell biology 123, 485-96. PMID: 7691831
5. Gao, AG. et al. (1996) The Journal of biological chemistry 271, 21-4. PMID: 8550562
6. Rogers, NM. et al. (2017) Cardiovascular research 113, 15-29. PMID: 27742621
7. Ghimire, K. et al. (2020) Cells 9. PMID: 32679764
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG4-Kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 3.5mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: LeukocytesurfaceantigenCD47,CD47,AntigenicsurfacedeterminantproteinOA3,IAP,Integrin-associatedprotein,ProteinMER6,MER6
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CD47,IBI-188,CAS:2283356-07-8
Background: Leukocyte surface antigen CD47 (MER6) is a ~35 kDa protein. Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. Involved in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Plays a role in modulating pulmonary endothelin EDN1 signaling. Modulates nitrous oxide (NO) signaling, in response to THBS1, hence playing a role as a pressor agent, supporting blood pressure. CD47 is the therapeutic target of magrolimab (clinical).
References:
1. Latour, S. et al. (2001) Journal of immunology (Baltimore, Md. : 1950) 167, 2547-54. PMID: 11509594
2. Piccio, L. et al. (2005) Blood 105, 2421-7. PMID: 15383453
3. Isenberg, JS. et al. (2009) The Journal of biological chemistry 284, 1116-25. PMID: 19004835
4. Lindberg, FP. et al. (1993) The Journal of cell biology 123, 485-96. PMID: 7691831
5. Gao, AG. et al. (1996) The Journal of biological chemistry 271, 21-4. PMID: 8550562
6. Rogers, NM. et al. (2017) Cardiovascular research 113, 15-29. PMID: 27742621
7. Ghimire, K. et al. (2020) Cells 9. PMID: 32679764
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
SDS-PAGESDS-PAGE for Research Grade Letaplimab
-
BioactivityDetects recombinant human CD47/MER6 (Catalog No: PH12099) in indirect ELISA
-
Flow cytometryFlow-cytometry using anti-human CD47 antibody. Hela cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human CD47 monoclonal antibody (Catalog HC359046, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.
